Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment
Higinio Dopeso, Silvia Mateo-Lozano, Elena Elez, Stefania Landolfi, Francisco Javier Ramos Pascual, Javier Hernandez-Losa, Rocco Mazzolini, Paulo Rodrigues, Sarah Bazzocco, Maria Josep Carreras, Eloy Espin, Manel Armengol, Andrew J Wilson, John M Mariadason, Santiago Ramon y Cajal, Josep Tabernero, Simo Schwartz, Diego Arango
CLINICAL CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2010
PURPOSE: Irinotecan (CPT11) treatment significantly improves the survival of colorectal cancer patients and is routinely used for the treatment of these patients, alone or in combination with other agents. However, only 20% to 30% of patients show an objective response to irinotecan, and there is great need for new molecular markers capable of identifying the subset of patients who are unlikely to respond. EXPERIMENTAL DESIGN: Here we used microarray analysis of a panel of 30 colorectal cancer cell lines and immunohistochemistry to identify and validate a new biomarker of response to irinotecan. RESULTS: A good correlation was observed between irinotecan sensitivity and the expression of apr..View full abstract
Awarded by Spanish Ministry of Science and Innovation
Spanish Ministry of Science and Innovation (FIS051394, CP05/00256, SAF2008-00789 and TRA2009-0093) and the Fundacion Medica Mutua Madrilena to D. Arango.